Advertisement

Modulation of Mammary Carcinogenesis by Eicosanoid Synthesis Inhibitors in Rats Fed High Levels of Linoleate

  • M. M. Ip
  • C. Ip
Chapter
Part of the Developments in Oncology book series (DION, volume 67)

Abstract

Diets containing relatively high amounts of polyunsaturated fat have been demonstrated to stimulate the development of a wide variety of mammary tumors in rodents (reviewed in ref. 1). Using the dimethylbenz(α)anthracene (DMBA)-induced mammary tumor model in rats, Carroll and Hopkins (2) reported that addition of as little as 3% of a linoleic acid-rich sunflower seed oil to a diet containing 17% beef tallow or coconut oil (saturated fats) was just as effective as a 20% sunflower seed oil diet in enhancing tumor development. Furthermore, rats on these diets produced twice as many tumors as those fed diets containing 20% of the saturated fats alone. These findings suggest that there may be a requirement for linoleate in mammary carcinogenesis that is not satisfied by fats such as beef tallow and coconut oil, but can be provided by adding 3% sunflower seed oil to diets containing these fats. More recently, we have shown that mammary tumorigenesis in the DMBA model was very sensitive to linoleate intake and increased proportionately in the range of 0.5% to 4% of dietary linoleate (3). Beyond this point and up to, 12% linoleate, there was no further enhancement, suggesting that the level of linoleate necessary to elicit the maximal tumorigenic response was around 4% by weight in the diet.

Keywords

Beef Tallow PGE2 Level Cyclooxygenase Inhibitor Mammary Carcinogenesis Mammary Tumorigenesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Welsch, C.W. and Aylsworth, C.F. J. Natl. Cancer Inst. 70: 215–221, 1983.PubMedGoogle Scholar
  2. 2.
    Carroll, K.K. and Hopkins, G.J. Lipids 14:155–158, 1979.PubMedCrossRefGoogle Scholar
  3. 3.
    Ip,C, Carter, C.A. and lp, M.M. Cancer Res. 45:1997–2001, 1985.PubMedGoogle Scholar
  4. 4.
    Welsch, C.W. Am. J. Clin. Nutr. 45: 192–202, 1987.PubMedGoogle Scholar
  5. 5.
    Rao, G. and Abraham, S. J. Natl. Cancer Inst. 58: 445–447, 1977.PubMedGoogle Scholar
  6. 6.
    Hillyard, L.A. and Abraham, S. Cancer Res. 39: 4430–4437, 1979.PubMedGoogle Scholar
  7. 7.
    Carter, C.A., Milholland, R.J., Shea, W.K. and Ip, M.M. Cancer Res. 43: 3559–3562, 1983.PubMedGoogle Scholar
  8. 8.
    Kollmorgan, G.M., King, M.M, Kosanke,S.D. and Do, C. Cancer Res. 43: 4714–4719, 1983.Google Scholar
  9. 9.
    Hubbard, N.E, Chapkin, R.S. and Erickson, K.L. Cancer Lett. 43: 111–120, 1988.PubMedCrossRefGoogle Scholar
  10. 10.
    Carter, C.A., Ip, M.M. and Ip, C. Carcinogenesis 10: 1369–1374, 1989.PubMedCrossRefGoogle Scholar
  11. 11.
    Ip, M.M., Mazzer, C, Watson, D. and Carter, C.A. Proc. Am. Assoc. Cancer Res. 30: 182 (Abstr. No. 721), 1989.Google Scholar
  12. 12.
    McCormick, D.L. and Moon, R.C. Brit. J. Cancer 48: 859–861 , 1983.CrossRefGoogle Scholar
  13. 13.
    McCormick, D.L, Madigan, M.J. and Moon, R.C. Cancer Res. 45:1803–1808, 1985.PubMedGoogle Scholar
  14. 14.
    Vanderhoek, J.Y. and Bailey, J.M. J. Biol. Chem. 259: 6752–6756, 1984.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • M. M. Ip
    • 1
  • C. Ip
    • 1
  1. 1.Grace Cancer Drug Center and Department of Breast SurgeryRoswell Park Cancer CenterBuffaloUSA

Personalised recommendations